Annual Report 2023: LEO Pharma Delivers 10% Revenue Growth and Returns to Positive EBITDA
LEO Pharma delivers a solid operational performance uplift with double-digit revenue growth and an EBITDA uplift of DKK 2.1 billion, corresponding to a 20%-points margin improvement.
- LEO Pharma delivers a solid operational performance uplift with double-digit revenue growth and an EBITDA uplift of DKK 2.1 billion, corresponding to a 20%-points margin improvement.
- LEO Pharma exceeded our profitability guidance and hit the upper range of our revenue growth guidance provided in March 2023.
- LEO Pharma delivered 11.4 billion in revenue, corresponding to 7% revenue growth in 2023.
- LEO Pharma exceeded our profitability guidance and hit the upper range of our revenue growth guidance provided in March 2023.